Acumen Pharmaceuticals (ABOS) Cash from Investing Activities (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 6 years of Cash from Investing Activities data on file, last reported at -$13.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 148.13% year-over-year to -$13.8 million; the trailing twelve-month figure through Mar 2026 stood at $91.4 million (up 6.42% YoY), and the FY2025 full-year result was $133.9 million, up 178.87% from the prior year.
• Cash from Investing Activities declined to -$13.8 million in Q1 2026, from $26.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $55.9 million in Q3 2022 to a low of -$92.0 million in Q3 2023.
• A 5-year average of $2.1 million and a median of $8.8 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 722.26% in 2023 and jumped 499.83% in 2025, its largest moves.
• Tracing ABOS's Cash from Investing Activities over 5 years: stood at -$20.4 million in 2022, then tumbled by 139.02% to -$48.8 million in 2023, then surged by 160.78% to $29.7 million in 2024, then slipped by 11.51% to $26.2 million in 2025, then slumped by 152.6% to -$13.8 million in 2026.
• Business Quant data shows ABOS's Cash from Investing Activities at -$13.8 million in Q1 2026, $26.2 million in Q4 2025, and $40.5 million in Q3 2025.